You are here

  • Home
  • Archive
  • Volume 22, Issue 2
  • SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Randomised controlled trial
SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease

https://doi.org/10.1136/ebmed-2016-110565

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests AJS worked as a clinical investigator enrolling four participants in this double-blind placebo-controlled EMPA-REG OUTCOME trial.

    • Provenance and peer review Commissioned; internally peer reviewed.